As the Science Committee of Kazakhstan’s Ministry of Education and Science reported, after 42 days of the new cure testing, the adaptive immunity has been revealed. The new Kazakhstani vaccine QazCovid-in was developed by scientists of the Research Institute for Biological Safety Problems of the Science Committee who also acted as test volunteers.
According to Kunsulu Zakarya, head of the institute, the scientists from the Medical School of Nankin University (China) might be wrong as they contend the immunity to COVID-19 disappears quickly. The research they made showed that the volume of antibodies to SARS-CoV-2 declined sharply after four weeks of recovery.
«Based on the results of our own research and traditionally deciphered patterns of immunology and epidemiology, we believe that the information published by Chinese scientists is unreliable or misinterpreted,» she said.
Kazakhstan’s institute has been examining blood serums of various people who recovered from COVID-19 since March.
«According to the results of the institute’s studies, all blood serum samples of people who already recovered (100%) and those who were vaccinated with an inactivated vaccine (100%) contain specific antibodies that neutralize the SARS-CoV-2 virus with a virulence of 3000 TCD50. In practice, to detect neutralizing antibodies scientists usually use a virus with a virulence of 100 TCD50. This proves that antibodies produced from blood serum of both recovered people and vaccinated volunteers have a strong ability to neutralize coronavirus. All volunteers among the institute’s employees are healthy, feel great and continue to work within the framework of the scientific and technical program,” stated Zakarya.
Earlier, Askhat Aymagambetov, head of the Ministry of Education and Science, announced that the preclinical trial of Kazakhstan’s inactivated vaccine QazCovid-in against COVID-19 showed promising results.
“As you know, we have finished preclinical trials. The vaccine developers and test volunteers are the same people. And now we have seen sharp growth of antibodies of immunoglobulin M and immunoglobulin G. The preclinical trials also show a high level of safety,» he said.
